Вортемиел

Вортемиел (Bortezomib) is a prescription medication used in cancer treatment. It belongs to the proteasome inhibitor class, targeting specific proteins in cancer cells. This EU-manufactured drug is administered via injection for systemic therapy.

Bortezomib is primarily used to treat multiple myeloma and mantle cell lymphoma, conditions affecting plasma cells in the blood. It works by interfering with proteins that help cancer cells grow, slowing their spread. Healthcare providers may also prescribe it for other off-label uses in certain cancer cases.

As a proteasome inhibitor, bortezomib helps reduce the growth of cancerous cells by disrupting their normal protein breakdown process. Patients may experience improved disease management over time with regular administration. Individual responses vary based on treatment protocols and medical conditions.

Bortezomib should only be handled and administered by trained medical professionals in a clinical setting. Patients must disclose all medications, including over-the-counter and herbal products, to avoid potential complications. Regular monitoring of blood counts and organ function is typically required during treatment.

Bortezomib may interact with medications that affect liver enzymes, such as CYP3A4 inhibitors or inducers, potentially altering its effectiveness. Combining it with other chemotherapy drugs or blood pressure medications could increase side effects. Alcohol and grapefruit products may also pose risks during treatment.